Search

Your search keyword '"Porter, Danielle"' showing total 319 results

Search Constraints

Start Over You searched for: Author "Porter, Danielle" Remove constraint Author: "Porter, Danielle"
319 results on '"Porter, Danielle"'

Search Results

2. SARS-CoV-2 RNA and Nucleocapsid Antigen Are Blood Biomarkers Associated With Severe Disease Outcomes That Improve in Response to Remdesivir.

4. Expanded profiling of Remdesivir as a broad-spectrum antiviral and low potential for interaction with other medications in vitro

6. A randomized controlled trial of presatovir for respiratory syncytial virus after lung transplant

8. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

9. Oral administration of obeldesivir protects nonhuman primates against Sudan ebolavirus

12. No Remdesivir Resistance Observed in the Phase 3 Severe and Moderate COVID-19 SIMPLE Trials

17. Clinical benefit of remdesivir in rhesus macaques infected with SARS-CoV-2

19. Non-nucleoside reverse transcriptase inhibitor (NNRTI) cross-resistance: implications for preclinical evaluation of novel NNRTIs and clinical genotypic resistance testing

20. Characterization of the Cynomolgus Macaque Model of Marburg Virus Disease and Assessment of Timing for Therapeutic Treatment Testing

23. Late remdesivir treatment initiation partially protects African green monkeys from lethal Nipah virus infection

24. Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

25. Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

26. Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study

27. Comparative therapeutic efficacy of remdesivir and combination lopinavir, ritonavir, and interferon beta against MERS-CoV

28. Safety, efficacy, and pharmacokinetics of a single-tablet regimen containing elvitegravir, cobicistat, emtricitabine, and tenofovir alafenamide in treatment-naive, HIV-infected adolescents: a single-arm, open-label trial

29. Prognostic value of severe acute respiratory syndrome coronavirus‐2 viral load and antibodies in patients hospitalized with COVID ‐19

32. 1149. Resistance Analyses of Patient Viral Samples from the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1)

33. 789. Viral and Immunologic biomarkers of COVID-19 improve risk stratification and identify patients most likely to benefit from therapy with remdesivir

35. Mutations in the SARS-CoV-2 RNA-dependent RNA polymerase confer resistance to remdesivir by distinct mechanisms

38. Intravenous delivery of GS-441524 is efficacious in the African green monkey model of SARS-CoV-2 infection

39. Remdesivir and GS-441524 Retain Antiviral Activity against Delta, Omicron, and Other Emergent SARS-CoV-2 Variants

40. Repurposing an In Vitro Measles Virus Dissemination Assay for Screening of Antiviral Compounds

44. Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease

46. Inhaled remdesivir reduces viral burden in a nonhuman primate model of SARS-CoV-2 infection

47. Distinct genetic determinants and mechanisms of SARS-CoV-2 resistance to remdesivir

48. Subcutaneous remdesivir administration prevents interstitial pneumonia in rhesus macaques inoculated with SARS-CoV-2

49. Characterization of Bombali Virus, a New Bat Filovirus

Catalog

Books, media, physical & digital resources